Trial · NCT02477826
Results by group40
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 40
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression-Free Survival Per BICR | Part 1-Arm B: Nivo + Ipi | 5.06 | 95% Confidence Interval 4.07 to 6.31 | months | |
| Progression-Free Survival Per BICR | Part 1-Arm A: Nivolumab | 4.17 | 95% Confidence Interval 3.22 to 5.32 | months | |
| Progression-Free Survival Per BICR | Part 1-Arm C: Chemotherapy | 5.55 | 95% Confidence Interval 4.63 to 5.82 | months | |
| Progression-Free Survival Per BICR | Part 1-Arm D: Nivo + Ipi | 4.90 | 95% Confidence Interval 3.15 to 6.28 | months | |
| Progression-Free Survival Per BICR | Part 1-Arm G: Nivo + Chemo | 5.55 | 95% Confidence Interval 4.63 to 6.90 | months | |
| Progression-Free Survival Per BICR | Part 1-Arm F: Chemotherapy | 4.70 | 95% Confidence Interval 4.21 to 5.59 | months | |
| Progression-Free Survival Per BICR | Part 2 - Arm H: Nivolumab + Chemotherapy | 8.34 | 95% Confidence Interval 7.10 to 9.59 | months | |
| Progression-Free Survival Per BICR | Part 2 - Arm I: Chemotherapy | 5.52 | 95% Confidence Interval 4.47 to 5.85 | months | |
| Progression-Free Survival Per BICR | Part 3 -Arm J: Nivolumab + Ipilimumab | 5.78 | 95% Confidence Interval 4.14 to 8.34 | months | |
| Progression-Free Survival Per BICR | Part 3 - Arm K: Chemotherapy | 5.49 | 95% Confidence Interval 4.37 to 6.77 | months | |
| Overall Survival | Part 1-Arm B: Nivo + Ipi | 17.12 | 95% Confidence Interval 14.95 to 20.17 | months | |
| Overall Survival | Part 1-Arm A: Nivolumab | 15.70 | 95% Confidence Interval 13.27 to 18.14 | months | |
| Overall Survival | Part 1-Arm C: Chemotherapy | 14.88 | 95% Confidence Interval 12.71 to 16.72 | months | |
| Overall Survival | Part 1-Arm D: Nivo + Ipi | 17.45 | 95% Confidence Interval 13.21 to 22.05 | months | |
| Overall Survival | Part 1-Arm G: Nivo + Chemo | 15.21 | 95% Confidence Interval 12.29 to 19.78 | months | |
| Overall Survival | Part 1-Arm F: Chemotherapy | 12.19 | 95% Confidence Interval 9.17 to 14.32 | months | |
| Overall Survival | Part 2 - Arm H: Nivolumab + Chemotherapy | 18.27 | 95% Confidence Interval 15.84 to 21.65 | months | |
| Overall Survival | Part 2 - Arm I: Chemotherapy | 14.72 | 95% Confidence Interval 12.42 to 16.79 | months | |
| Overall Survival | Part 3 -Arm J: Nivolumab + Ipilimumab | 20.99 | 95% Confidence Interval 16.95 to 25.17 | months | |
| Overall Survival | Part 3 - Arm K: Chemotherapy | 15.11 | 95% Confidence Interval 13.17 to 18.89 | months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02477826/results